Novel epigallocatechin-3-gallate (EGCG) derivative as a new therapeutic strategy for reducing neuropathic pain after chronic constriction nerve injury in mice

• Published in: PloS one 2015-04, Vol.10 (4), p.e0123122-e0123122
• Main Authors: Xifró, Xavier, Vidal-Sancho, Laura, Boadas-Vaello, Pere, Turrado, Carlos, Alberch, Jordi, Puig, Teresa, Verdú, Enrique
• Format: Article
• Language: English
• Subjects: Animals; Catechin; Catechin - administration & dosage; Catechin - analogs & derivatives; Cell Membrane - drug effects; Cell Membrane - metabolism; Cytokines; Cytokines - biosynthesis; Cytokines - metabolism; Derivatives; Dolor; Dolor neuropàtic; Dorsal horn; Epigallocatechin gallate; Epigallocatechin-3-gallate; Fatty Acid Synthase, Type I - biosynthesis; Fatty Acid Synthase, Type I - metabolism; Fatty acids; Fatty Acids - metabolism; Fatty-acid synthase; Gene Expression Regulation - drug effects; Glutamate receptors; Glutamic acid receptors; Health aspects; Hyperalgesia; Hyperalgesia - drug therapy; Hyperalgesia - metabolism; Hyperalgesia - physiopathology; Inflammation; Injuries; Injury prevention; Kinases; Laboratories; Latency; Localization; Male; Methods; Mice; Molecular modelling; N-Methyl-D-aspartic acid receptors; Nervous system; Neuralgia; Neuralgia - drug therapy; Neuralgia - metabolism; Neuralgia - physiopathology; Neuropathy; Neuràlgia; NF-κB protein; Nitric oxide; Pain; Pain - drug therapy; Pain - metabolism; Pain - physiopathology; Pain management; Pain perception; Pain Threshold; Peripheral Nerve Injuries; Peripheral nerves; Peripheral neuropathy; Physiological aspects; Polyphenols; Proteins; Rodents; Spinal cord; Spinal Cord Injuries - drug therapy; Spinal Cord Injuries - metabolism; Spinal Cord Injuries - physiopathology; Tractament; Treatment
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0123122

Neuropathic pain is common in peripheral nerve injury and often fails to respond to ordinary medication. Here, we investigated whether the two novel epigallocatechin-3-gallate (EGCG) polyphenolic derivatives, compound 23 and 30, reduce the neuropathic pain in mice chronic constriction nerve injury (CCI). First, we performed a dose-response study to evaluate nociceptive sensation after administration of EGCG and its derivatives 23 and 30, using the Hargreaves test at 7 and 21 days after injury (dpi). We daily administered EGCG, 23 and 30 (10 to 100 mg/Kg; i.p.) during the first week post-CCI. None of the doses of compound 23 caused significant pain diminution, whereas 50mg/kg was optimal for both EGCG and 30 to delay the latency of paw withdrawal. With 50 mg/Kg, we showed that EGCC prevented the thermal hyperalgesia from 7 to 21 dpi and compound 30 from 14 to 56 dpi. To evaluate the molecular mechanisms underpinning why EGCG and compound 30 differentially prevented the thermal hyperalgesia, we studied several biochemical parameters in the dorsal horn of the spinal cord at 14 and 56 dpi. We showed that the effect observed with EGCG and compound 30 was related to the inhibition of fatty acid synthase (FASN), a known target of these polyphenolic compounds. Additionally, we observed that EGCG and compound 30 reduced the expression of CCI-mediated inflammatory proteins and the nuclear localization of nuclear factor-kappa B at 14 dpi, but not at 56 dpi. We also strongly detected a decrease of synaptic plasma membrane levels of N-methyl-D-asparte receptor 2B in CCI-mice treated with compound 30 at 56 dpi. Altogether, compound 30 reduced the chronic thermal hyperalgesia induced by CCI better than the natural compound EGCG. Thus, our findings provide a rationale for the preclinical development of compound 30 as an agent to treat neuropathic pain.